

sub
B1
AI
cont

X¹ is -C(=X³)-N(R⁸)-;

X² is C(=X³);

X³ is O;

R¹ is acyl of 18 carbons;

R² is H;

R³ is ethylene;

R⁴ is acyl of 18 carbons;

R⁵ is H;

R⁶ is a direct bond;

R⁷ is ethylene;

R⁸ is H;

P is PEG-3400; and

T comprises a peptide having the sequence CRGDC, wherein the two cysteines are linked together via a disulfide linkage.

55. (Added) A targeted vesicle composition for therapeutic or diagnostic use *in vivo* comprising, in an aqueous carrier, lipid vesicles, wherein said vesicles comprise a compound according to Claim 54.

sub
B1

56. (Added) A targeted vesicle composition according to Claim 55 wherein said lipid vesicles comprise a phospholipid selected from the group consisting of phosphatidylcholine, phosphatidylethanolamine and phosphatidic acid.

A1
Cmt

57. (Added) A targeted vesicle composition according to Claim 56 wherein said phosphatidylethanolamine comprises dipalmitoylphosphatidylethanolamine.

58. (Added) A targeted vesicle composition according to Claim 55, wherein said vesicles comprise a gas selected from the group consisting of perfluorocarbons and sulfur hexafluoride.

59. (Added) A targeted vesicle composition according to Claim 58, wherein said vesicles comprise perfluorobutane.

60. (Added) A targeted vesicle composition according to Claim 55, further comprising urokinase.

REMARKS

Reconsideration of the present application in view of the above amendments and following remarks is respectfully requested.